Novavax vaccine poised to be a fourth COVID-19 option in U.S.

Maryland drugmaker Novavax is playing catch-up in the COVID-19 vaccine race but feels it can sway the vaccine-hesitant and serve the long-term booster market when U.S. regulators give the green light to its shots.

from The Washington Times stories: Health https://ift.tt/x2B3keA